THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL

Rubic-Schneider Tina; Garcia Deborah; Marchant Martine; Christen Brigitte; Runser-Loll Nathalie; Rush James; Traggiai Elisabetta; Ulrich Peter

首页> 外文期刊>Transplant international : >THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL

【24h】

THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL

机译：抗CD40 mAb iscalimab（CFZ533）不会损害免疫EBV控制

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Transplant international :》 |2019年第s2期|共1页
作者
Rubic-Schneider Tina; Garcia Deborah; Marchant Martine; Christen Brigitte; Runser-Loll Nathalie; Rush James; Traggiai Elisabetta; Ulrich Peter;
展开▼
作者单位

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

Novartis Inst Biomed Res Basel Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类器官移植术;
关键词

相似文献

外文文献
中文文献
专利

1. THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL [J] . Rubic-Schneider Tina, Garcia Deborah, Marchant Martine, Transplant international : . 2019,第S2期

机译：抗CD40 mAb iscalimab（CFZ533）不会损害免疫EBV控制
2. CIRRUS I - STUDY: EVALUATION OF EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-CD40 ANTIBODY ISCALIMAB (CFZ533) IN RENAL TRANSPLANT RECIPIENTS - STUDY RATIONALE AND DESIGN [J] . Thaiss F., Vincenti F., Citterio F., Transplant international : . 2019,第S3期

机译：Cirrus I - 研究：肾移植受者抗CD40抗体异丙嘧啶（CFZ533）的疗效，安全，药代动力学和药效学评估 - 研究理由和设计
3. EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY ISCALIMAB (CFZ533) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: RATIONALE AND DESIGN OF THE CONTRAIL I STUDY [J] . Knechtle Stuart J., Saliba Faouzi, Nashan Bjorn, Transplant international : . 2019,第S2期

机译：抗CD40单克隆抗体Iscalimab（CFZ533）的疗效，安全，药代动力学和药效学和药效学（CFZ533）在De Novo肝脏移植受者：我学习的轨迹的理由和设计
4. Stability and Hopf Bifurcation in a Viral Infection Model with Immune Impairment and Delayed Immune Response [C] . Zhiping Wang, Rui Xu, Feilong Hao International congress on mathematical biology;ICMB2011 . 2011

机译：免疫受损和免疫反应延迟的病毒感染模型的稳定性和Hopf分叉
5. Cathepsin-dependent lysosome rupture controls cell death, Nalp3 impairment, and adaptive immunity by the adjuvants alum and Leu-Leu-OMe [D] . Jacobson, Lee Stuart 2013

机译：依赖组织蛋白酶的溶酶体破裂控制明矾和Leu-Leu-OMe佐剂的细胞死亡，Nalp3损伤和适应性免疫
6. Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma [O] . Jingzhe Zhang, Ye Li, Shoujun Yang, 2019

机译：抗CD40 mAb增强抗PD1抗骨肉瘤的功效
7. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study [O] . Benjamin A Fisher, Antonia Szanto, Wan-Fai Ng, 2020

机译：评估抗CD40抗体异霉素在原发性Sjögren综合征患者中：多期，随机，双盲，安慰剂控制，概念证明研究
8. User Manual for the Miniature Armor Battlefield (MAB). Appendix C. Criterion Tests. Appendix D. How to Construct Terrain Features. Appendix E. Details of Radio Control Equipment. Appendix F. Housing and Training Platform for the MAB. [R] . 1962

机译：微型装甲战场用户手册（maB）。附录C.标准测试。附录D.如何构建地形特征。附录E.无线电控制设备的细节。附录F.人与生物圈计划的住房和培训平台。

THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL

著录项

引文网络

相似文献

相关主题

期刊订阅